<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181986</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-CT-31</org_study_id>
    <nct_id>NCT01181986</nct_id>
  </id_info>
  <brief_title>The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes</brief_title>
  <official_title>Exenatide and Postprandial Endothelial Dysfunction: Effects and Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl T. Hayden VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Carl T. Hayden VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to evaluate whether exenatide, a type 2 diabetes
      medication, will improve the function of the innermost part of the arterial wall called the
      endothelium after a fat-enriched meal and to determine how this occurs. The results of this
      study will help to determine and understand a novel action of this group of diabetes
      medications based on the action of naturally occuring gut substances called incretins. This
      may have a significant impact on cardiovascular health in patients with early and
      longstanding diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two independent, double-blinded, crossover substudies will be conducted to test the effect of
      exenatide on daylong post-meal and fasting endothelial function. We will measure endothelial
      function measured by peripheral arterial tonometry (EndoPAT2000, Itamar Inc.). Patients with
      recent onset (&lt;3 years) or established (&gt;5 years, Substudy 1 only) diabetes and impaired
      sugar tolerance (Substudy 2 only) will be studied. The plan is to complete studies in 75
      patients (40 in Substudy 1 and 35 in Substudy 2).

      In Substudy 1 patients will get twice a day a skin injection of exenatide (Byetta) or
      identically looking placebo for 10 days, separated by 14-day period. On the next day after
      each treatemnt period (day 11), they get just one injection and eat a fat-enriched breakfast.
      A fatty lunch of similar caloric content will be given 4 hours following the breakfast.
      Endothelial function will be measured just prior to the injection and every 2 hours for total
      8 hours.

      In Substudy 2, patients on 3 different days will get infusion of exenatide withg or without a
      blocking drug exendin-9, and a control test with placebo without exendin-9. Endothelial
      function will be measured before the infusion and 2 hours later during the final 15 minutes
      of the infusion cocktails. Patients will not eat any meal during the test visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 &amp; 3 (Sub-study 2)</time_frame>
    <description>Greater RHI reflects greater endothelial function. It is calculated as average post-ischemia pulse magnitude divided by average pre-ischemia pulse magnitude. Results are expressed as least-square means of ANCOVA models.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Triglycerides</measure>
    <time_frame>0, 2, 4, 6 and 8 hours post-study drug on day 11</time_frame>
    <description>Triglycerides concentrations were measured before and 2, 4, 6 and 8 hours following study drug. Results are expressed as least-square means of ANCOVA models adjusted for sampling time and intervention sequence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose</measure>
    <time_frame>0, 2, 4, 6, and 8 hours post-study drug on day 11</time_frame>
    <description>Plasma glucose was measured before and 2, 4, 6 and 8 hours following study drug administration. Results are expressed as least-square means of ANCOVA models adjusted for sampling time and intervention sequence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Exenatide SC (Sub-study 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study groups will be individuals with recent onset (&lt;3 years) or established (&gt;5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide IV (Sub-study 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group will be individuals with recent onset (&lt;1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide SC</intervention_name>
    <description>Exenatide 5-10 ug sc BID/10 days</description>
    <arm_group_label>Exenatide SC (Sub-study 1)</arm_group_label>
    <other_name>Byetta, exendin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide IV</intervention_name>
    <description>50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days</description>
    <arm_group_label>Exenatide IV (Sub-study 2)</arm_group_label>
    <other_name>exendin-4, Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Placebo sc BID/10days</description>
    <arm_group_label>Exenatide SC (Sub-study 1)</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-9</intervention_name>
    <description>Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.</description>
    <arm_group_label>Exenatide IV (Sub-study 2)</arm_group_label>
    <other_name>exendin-(9-39)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Intravenous infusion for 45 minutes on 1 out of 3 visits</description>
    <arm_group_label>Exenatide IV (Sub-study 2)</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  US Veterans

          -  type 2 diabetes mellitus (T2D) diagnosed within 3 years with good glycemic control on
             diet, metformin, or sulfonylurea agents or combinations of these agents (HbA1c ≤8.0%)

          -  T2D diagnosed ≥ 5 years prior to study enrollment

          -  Impaired glucose tolerance

        Exclusion Criteria:

          -  T2D not meeting inclusion above criteria for duration of diabetes or HbA1c values

          -  known or suspected T1D (early onset age, low body mass index, lack of family history)

          -  TZD use in the prior 3 months

          -  prior regular use of insulin

          -  Creatinine &gt;2.0 mg/dl or other laboratory or clinical evidence of kidney disease

          -  anemia

          -  known active liver disease or hepatic enzyme elevation two-and-a half times above
             normal

          -  acute bacterial or viral illness or evidence of other active infection in the past 4
             weeks

          -  stable or unstable angina or other major illness in the past 6 months

          -  Raynaud's disease or any rheumatic disease affecting fingers

          -  current regular use of anti-inflammatory medications or antioxidants, including over
             the counter medications and high dose salicylates (&gt;1 g/day);

          -  subjects receiving lipid lowering or anti-hypertension medications must be on stable
             doses for at least 2 months prior to participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juraj Koska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix VA Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix VA Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <results_first_submitted>December 26, 2013</results_first_submitted>
  <results_first_submitted_qc>April 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2014</results_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carl T. Hayden VA Medical Center</investigator_affiliation>
    <investigator_full_name>Juraj Koska</investigator_full_name>
    <investigator_title>Research Health Scientist</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus, Impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exenatide Then Placebo (Sub-study 1)</title>
          <description>Patients received exenatide 5-10 ug sc BID for 10 days. On day 11, after receiving AM dose, vascular and blood parameters responses to study meal were tested.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Exenatide (Sub-study 1)</title>
          <description>Patients received placebo sc BID for 10 days. On day 11, after receiving AM dose, vascular and blood parameters responses to study meal were tested.</description>
        </group>
        <group group_id="P3">
          <title>Exenatide IV (Sub-study 2)</title>
          <description>Patients received in random order on single day an intravenous infusion of (1) Saline+Exenatide, (2) Exendin-9+Exenatide or (3) Saline+Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Saline+Exenatide</title>
              <participants_list>
                <participants group_id="P1" count="0">N/A for this arm</participants>
                <participants group_id="P2" count="0">N/A for this arm</participants>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Saline+Placebo</title>
              <participants_list>
                <participants group_id="P1" count="0">N/A for this arm</participants>
                <participants group_id="P2" count="0">N/A for this arm</participants>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exendin-9+Exenatide</title>
              <participants_list>
                <participants group_id="P1" count="0">N/A for this arm</participants>
                <participants group_id="P2" count="0">N/A for this arm</participants>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0">N/A for Sub-study 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sub-study 1: Exenatide SC</title>
          <description>Exenatide 5-10 ug or placebo sc BID/10 days, day 11 AM dose and meal test - crossover study</description>
        </group>
        <group group_id="B2">
          <title>Sub-study 2: Exenatide IV</title>
          <description>Intravenous infusion of (1) Saline+Exenatide, (2) Saline+Placebo or (3) Exendin-9+Exenatide on 3 seperate days, crossover study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="6"/>
                    <measurement group_id="B2" value="60" spread="6"/>
                    <measurement group_id="B3" value="61" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="6"/>
                    <measurement group_id="B2" value="33" spread="12"/>
                    <measurement group_id="B3" value="33" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="0.9"/>
                    <measurement group_id="B2" value="6.1" spread="0.5"/>
                    <measurement group_id="B3" value="6.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration (years)</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="B3" value="6" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic BP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128" spread="8"/>
                    <measurement group_id="B2" value="125" spread="12"/>
                    <measurement group_id="B3" value="127" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic BP (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="8"/>
                    <measurement group_id="B2" value="80" spread="8"/>
                    <measurement group_id="B3" value="79" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid-lowering therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reactive Hyperemia Index (RHI)</title>
        <description>Greater RHI reflects greater endothelial function. It is calculated as average post-ischemia pulse magnitude divided by average pre-ischemia pulse magnitude. Results are expressed as least-square means of ANCOVA models.</description>
        <time_frame>0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 &amp; 3 (Sub-study 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide (Subs-study 1)</title>
            <description>Exenatide: Exenatide 5-10 ug sc BID/10 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Sub-study 1)</title>
            <description>Placebo sc BID for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Saline+Exenatide (Sub-study 2)</title>
            <description>Infusion of saline (min 0-75), added exenatide infusion (min 30-75)</description>
          </group>
          <group group_id="O4">
            <title>Saline+Placebo (Sub-study 2)</title>
            <description>Infusion of saline (min 0-75), added placebo infusion (min 30-75)</description>
          </group>
          <group group_id="O5">
            <title>Exendin-9+Exenatide (Sub-study 2)</title>
            <description>Infusion of exendin-9 (min 0-75), added exenatide infusion (min 30-75)</description>
          </group>
        </group_list>
        <measure>
          <title>Reactive Hyperemia Index (RHI)</title>
          <description>Greater RHI reflects greater endothelial function. It is calculated as average post-ischemia pulse magnitude divided by average pre-ischemia pulse magnitude. Results are expressed as least-square means of ANCOVA models.</description>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.005"/>
                    <measurement group_id="O2" value="1.79" spread="0.05"/>
                    <measurement group_id="O3" value="2.24" spread="0.07"/>
                    <measurement group_id="O4" value="1.95" spread="0.07"/>
                    <measurement group_id="O5" value="1.99" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for treatment sequence, group (diabetes duration) and time.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for treatment sequence.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for treatment sequence.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Triglycerides</title>
        <description>Triglycerides concentrations were measured before and 2, 4, 6 and 8 hours following study drug. Results are expressed as least-square means of ANCOVA models adjusted for sampling time and intervention sequence.</description>
        <time_frame>0, 2, 4, 6 and 8 hours post-study drug on day 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide (Sub-study 1)</title>
            <description>Patients received exenatide 5-10 ug sc BID for 10 days. On day 11, after receiving AM dose, vascular and blood parameters responses to study meal were tested.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Sub-study 1)</title>
            <description>Patients received placebo sc BID for 10 days. On day 11, after receiving AM dose, vascular and blood parameters responses to study meal were tested.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Triglycerides</title>
          <description>Triglycerides concentrations were measured before and 2, 4, 6 and 8 hours following study drug. Results are expressed as least-square means of ANCOVA models adjusted for sampling time and intervention sequence.</description>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" spread="14"/>
                    <measurement group_id="O2" value="230" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for treatment sequence and diabetes duration group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose</title>
        <description>Plasma glucose was measured before and 2, 4, 6 and 8 hours following study drug administration. Results are expressed as least-square means of ANCOVA models adjusted for sampling time and intervention sequence.</description>
        <time_frame>0, 2, 4, 6, and 8 hours post-study drug on day 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide (Sub-study 1)</title>
            <description>Patients received exenatide 5-10 ug sc BID for 10 days. On day 11, after receiving AM dose, vascular and blood parameters responses to study meal were tested.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Sub-study 1)</title>
            <description>Patients received placebo sc BID for 10 days. On day 11, after receiving AM dose, vascular and blood parameters responses to study meal were tested.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose</title>
          <description>Plasma glucose was measured before and 2, 4, 6 and 8 hours following study drug administration. Results are expressed as least-square means of ANCOVA models adjusted for sampling time and intervention sequence.</description>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="5"/>
                    <measurement group_id="O2" value="136" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exenatide SC (Sub-study 1)</title>
          <description>Exenatide 5-10 ug sc BID/10 days, AM dose and meal test on day 11</description>
        </group>
        <group group_id="E2">
          <title>Placebo SC (Sub-study 1)</title>
          <description>Placebo sc BID/10days, AM dose and meal test on day 11</description>
        </group>
        <group group_id="E3">
          <title>Saline+Exenatide IV (Sub-study 2)</title>
          <description>Intravenous infusion of saline (min 0-75), added intravenous infusion of exenatide (min30-75)</description>
        </group>
        <group group_id="E4">
          <title>Saline+Placebo (Sub-study 2)</title>
          <description>Intravenous infusion of saline (min 0-75), added intravenous infusion of placebo (min30-75)</description>
        </group>
        <group group_id="E5">
          <title>Exendin-9+Exenatide IV (Sub-study 2)</title>
          <description>Intravenous infusion of exendin-9 (min 0-75), added intravenous infusion of placebo (min30-75)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>The event occured 13 days after the test visit during which patient received intravenous infusion of saline with placebo. The event was considered unrelated to the study per IRB decision.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juraj Koska</name_or_title>
      <organization>Phoenix VA Health Care System</organization>
      <phone>602-277-5551 ext 7685</phone>
      <email>juraj.koska@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

